5 completed, 3 terminated, 1 unknown. 9 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 5, Terminated 3, Unknown 1 |
| Phase 1 | 3 | Completed 2, Unknown 1 |
Follow Threshold Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours TH-302 + Sunitinib - Neuroendocrine Tumors, Pancreatic Neoplasms | Phase 2 | Completed | Grupo Espanol de Tumores Neuroendocrinos | 17 | 2015-05-11 | 2020-07-27 |
| Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer TH-302 monotherapy - Biliary Tract Cancer | Phase 2 | Completed | Seoul National University Hospital | 24 | 2015-04-01 | 2018-09-10 |
| A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma TH-302, Doxorubicin - Soft Tissue Sarcoma | Phase 2 | Terminated | Merck KGaA, Darmstadt, Germany | 6 | 2014-12-10 | 2018-12-14 |
| Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma TH-302, TH-302 and Dexamethasone, TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Threshold Pharmaceuticals | 98 | 2012-02-01 | 2016-06-02 |
| Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors TH-302 - Non-Small Cell Lung Cancer, Prostate Cancer | Phase 1 / Phase 2 | Completed | Threshold Pharmaceuticals | 71 | 2008-08-01 | 2015-05-07 |
| Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma Glufosfamide - Soft Tissue Sarcoma | Phase 2 | Completed | Eleison Pharmaceuticals LLC. | 22 | 2007-03-01 | 2015-03-25 |
| Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma Glufosfamide - Carcinoma, Small Cell Lung | Phase 2 | Terminated | Threshold Pharmaceuticals | 50 | 2007-02-01 | 2009-04-30 |
| Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia Lonidamine - Benign Prostatic Hyperplasia | Phase 2 | Terminated | Threshold Pharmaceuticals | 240 | 2005-06-01 | 2009-04-29 |
| Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer Glufosfamide, Gemcitabine - Neoplasms, Pancreatic Neoplasms | Phase 1 / Phase 2 | Completed | Threshold Pharmaceuticals | 47 | 2004-12-01 | 2009-04-30 |
Pancreatic Neoplasms (3) · Hypoxia (2) · Sarcoma (2) · Biliary Tract Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Multiple Myeloma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neoplasms, Plasma Cell (1) · Neuroectodermal Tumors, Primitive (1) · Neuroendocrine Tumors (1) · Prostatic Hyperplasia (1) · Prostatic Neoplasms (1) · Small Cell Lung Carcinoma (1)
TH 302 (4) · beta-D-glucosylisophosphoramide mustard (3) · Bortezomib (1) · Dexamethasone (1) · Doxorubicin (1) · Gemcitabine (1) · Sunitinib (1) · lonidamine (1) · pomalidomide (1)
United States (6) · Brazil (1) · Japan (1) · South Korea (1) · Spain (1)
Claire Verschraegen, MD (1) · David Mendelson, MD (1) · Do-Youn Oh, MD, PhD (1) · Douglas Adkins, MD (1) · Enrique Grande, MD (1) · Gerald Rosen, MD (1) · Gerold Bepler, MD, PhD (1) · Gina D'Amato, MD (1) · Jeffrey R Infante, MD (1) · John C Ruckdeschel, MD (1) · Kristen Ganjoo, MD (1) · Lee Cranmer, MD, PhD (1) · Mitesh Borad, MD (1) · Peter D Eisenberg, MD (1)
2014 (1)